Literature DB >> 29296746

Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels.

Qianyi Ma1, Paula M Jacobi2, Brian T Emmer3, Colin A Kretz4, Ayse Bilge Ozel1, Beth McGee5, Chava Kimchi-Sarfaty6, David Ginsburg1,2,3,4, Jun Z Li1,7, Karl C Desch2.   

Abstract

The metalloprotease ADAMTS13 cleaves von Willebrand factor (VWF) in circulating blood, limiting the size of VWF multimers and regulating VWF activity. Abnormal regulation of VWF contributes to bleeding and to thrombotic disorders. ADAMTS13 levels in plasma are highly variable among healthy individuals, although the heritability and the genetic determinants of this variation are unclear. We performed genome-wide association studies of plasma ADAMTS13 concentrations in 3244 individuals from 2 independent cohorts of healthy individuals. The heritability of ADAMTS13 levels was between 59.1% (all individuals) and 83.5% (siblings only), whereas tobacco smoking was associated with a decrease in plasma ADAMTS13 levels. Meta-analysis identified common variants near the ADAMTS13 locus on chromosome 9q34.2 that were significantly associated with ADAMTS13 levels and collectively explained 20.0% of the variance. The top single nucleotide polymorphism (SNP), rs28673647, resides in an intron of ADAMTS13 (β, 6.7%; P = 1.3E-52). Conditional analysis revealed 3 additional independent signals represented by rs3739893 (β, -22.3%; P = 1.2E-30) and rs3124762 (β, 3.5%; P = 8.9E-9) close to ADAMTS13 and rs4075970 (β, 2.4%; P = 6.8E-9) on 21q22.3. Linkage analysis also identified the region around ADAMTS13 (9q34.2) as the top signal (LOD 3.5), consistent with our SNP association analyses. Two nonsynonymous ADAMTS13 variants in the top 2 independent linkage disequilibrium blocks (Q448E and A732V) were identified and characterized in vitro. This study uncovered specific common genetic polymorphisms that are key genetic determinants of the variation in plasma ADAMTS13 levels in healthy individuals.

Entities:  

Year:  2017        PMID: 29296746      PMCID: PMC5728318          DOI: 10.1182/bloodadvances.2017005629

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  37 in total

1.  Predictors of in-hospital mortality and acute myocardial infarction in thrombotic thrombocytopenic purpura.

Authors:  Nivas Balasubramaniyam; Dhaval Kolte; Chandrasekar Palaniswamy; Kiran Yalamanchili; Wilbert S Aronow; John A McClung; Sahil Khera; Sachin Sule; Stephen J Peterson; William H Frishman
Journal:  Am J Med       Date:  2013-08-29       Impact factor: 4.965

2.  Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance.

Authors:  A B Ozel; B McGee; D Siemieniak; P M Jacobi; S L Haberichter; L C Brody; J L Mills; A M Molloy; D Ginsburg; J Z Li; K C Desch
Journal:  J Thromb Haemost       Date:  2016-08-19       Impact factor: 5.824

3.  Allosteric activation of ADAMTS13 by von Willebrand factor.

Authors:  Joshua Muia; Jian Zhu; Garima Gupta; Sandra L Haberichter; Kenneth D Friedman; Hendrik B Feys; Louis Deforche; Karen Vanhoorelbeke; Lisa A Westfield; Robyn Roth; Niraj Harish Tolia; John E Heuser; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

4.  Smoking, von Willebrand factor and ADAMTS-13 in healthy males.

Authors:  Anwar M Al-Awadhi; Mehrez M Jadaon; Faisal A Alsayegh; Seham K Al-Sharrah
Journal:  Scand J Clin Lab Invest       Date:  2012-10-01       Impact factor: 1.713

5.  ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men.

Authors:  Chan K N K Chion; Carine J M Doggen; James T B Crawley; David A Lane; Frits R Rosendaal
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

6.  Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions.

Authors:  Amber L Couzens; James D R Knight; Michelle J Kean; Guoci Teo; Alexander Weiss; Wade H Dunham; Zhen-Yuan Lin; Richard D Bagshaw; Frank Sicheri; Tony Pawson; Jeffrey L Wrana; Hyungwon Choi; Anne-Claude Gingras
Journal:  Sci Signal       Date:  2013-11-19       Impact factor: 8.192

7.  Analysis of informed consent document utilization in a minimal-risk genetic study.

Authors:  Karl Desch; Jun Li; Scott Kim; Naomi Laventhal; Kristen Metzger; David Siemieniak; David Ginsburg
Journal:  Ann Intern Med       Date:  2011-09-06       Impact factor: 25.391

Review 8.  von Willebrand factor assembly and secretion.

Authors:  J E Sadler
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

9.  GTRD: a database of transcription factor binding sites identified by ChIP-seq experiments.

Authors:  Ivan Yevshin; Ruslan Sharipov; Tagir Valeev; Alexander Kel; Fedor Kolpakov
Journal:  Nucleic Acids Res       Date:  2016-10-24       Impact factor: 16.971

10.  Systematic identification of trans eQTLs as putative drivers of known disease associations.

Authors:  Harm-Jan Westra; Marjolein J Peters; Tõnu Esko; Hanieh Yaghootkar; Claudia Schurmann; Johannes Kettunen; Mark W Christiansen; Bruce M Psaty; Samuli Ripatti; Alexander Teumer; Timothy M Frayling; Andres Metspalu; Joyce B J van Meurs; Lude Franke; Benjamin P Fairfax; Katharina Schramm; Joseph E Powell; Alexandra Zhernakova; Daria V Zhernakova; Jan H Veldink; Leonard H Van den Berg; Juha Karjalainen; Sebo Withoff; André G Uitterlinden; Albert Hofman; Fernando Rivadeneira; Peter A C 't Hoen; Eva Reinmaa; Krista Fischer; Mari Nelis; Lili Milani; David Melzer; Luigi Ferrucci; Andrew B Singleton; Dena G Hernandez; Michael A Nalls; Georg Homuth; Matthias Nauck; Dörte Radke; Uwe Völker; Markus Perola; Veikko Salomaa; Jennifer Brody; Astrid Suchy-Dicey; Sina A Gharib; Daniel A Enquobahrie; Thomas Lumley; Grant W Montgomery; Seiko Makino; Holger Prokisch; Christian Herder; Michael Roden; Harald Grallert; Thomas Meitinger; Konstantin Strauch; Yang Li; Ritsert C Jansen; Peter M Visscher; Julian C Knight
Journal:  Nat Genet       Date:  2013-09-08       Impact factor: 38.330

View more
  4 in total

1.  The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension.

Authors:  Michael Newnham; Kieron South; Marta Bleda; William R Auger; Joan A Barberà; Harm Bogaard; Katherine Bunclark; John E Cannon; Marion Delcroix; Charaka Hadinnapola; Luke S Howard; David Jenkins; Eckhard Mayer; Choo Ng; Christopher J Rhodes; Nicholas Screaton; Karen Sheares; Michael A Simpson; Mark Southwood; Li Su; Dolores Taboada; Matthew Traylor; Richard C Trembath; Sofia S Villar; Martin R Wilkins; John Wharton; Stefan Gräf; Joanna Pepke-Zaba; Michael Laffan; David A Lane; Nicholas W Morrell; Mark Toshner
Journal:  Eur Respir J       Date:  2019-03-28       Impact factor: 16.671

2.  Blood Group O Protect End-Stage Renal Disease Patients With Dialysis From Coronary Artery Disease.

Authors:  Zixiang Ye; Yaxin Wu; Yimin Tu; Mulei Chen; Yanxiang Gao; Linying Shi; Peizhao Li; Enmin Xie; Ziyu Guo; Qing Li; Xiaozhai Yu; Yike Li; Wenquan Niu; Jingyi Ren; Jingang Zheng
Journal:  Front Cardiovasc Med       Date:  2022-01-28

Review 3.  Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus.

Authors:  Upendra K Katneni; Aikaterini Alexaki; Ryan C Hunt; Tal Schiller; Michael DiCuccio; Paul W Buehler; Juan C Ibla; Chava Kimchi-Sarfaty
Journal:  Thromb Haemost       Date:  2020-08-24       Impact factor: 5.249

4.  Verification of the Role of ADAMTS13 in the Cardiovascular Disease Using Two-Sample Mendelian Randomization.

Authors:  Zixiang Ye; Jingang Zheng
Journal:  Front Genet       Date:  2021-07-01       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.